Enveric Biosciences (ENVB) Restructuring Costs (2016 - 2018)
Enveric Biosciences (ENVB) posted Restructuring Costs of $95285.0 for Q4 2018, down 58.2% sequentially from $227952.0 in Q3 2018, and up 4.77% YoY from $90949.0 in Q4 2017.
Enveric Biosciences (ENVB) Restructuring Costs (2016 - 2018) Analysis & Trends
Enveric Biosciences has reported Restructuring Costs for 3 years, with the latest figure at $95285.0 in Q4 2018.
- Quarterly Restructuring Costs rose 4.77% year-over-year to $95285.0 in Q4 2018, while the trailing twelve-month figure through Sep 2019 was $95285.0 (down 71.03% YoY) and the FY2018 annual result came in at $333237.0, down 30.74% from the prior year.
- Restructuring Costs slipped to $95285.0 in Q4 2018 per ENVB's latest filing, from $227952.0 in the prior quarter.
- Over five years, Restructuring Costs peaked at $1.0 million in Q3 2016 and troughed at -$45642.0 in Q4 2016.
- A 3-year average of $218136.0 and a median of $175136.0 in 2017 frame the typical range for Restructuring Costs.
- The sharpest annual moves came in 2017 and 2018: Restructuring Costs plunged 99.44% in 2017, then soared 3903.37% in 2018.
- Over 3 years, Restructuring Costs stood at -$45642.0 in 2016, then surged by 299.27% to $90949.0 in 2017, then gained by 4.77% to $95285.0 in 2018.
- According to Business Quant data, Restructuring Costs over the past three periods registered $95285.0, $227952.0, and $10000.0 for Q4 2018, Q3 2018, and Q1 2018 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Enveric Biosciences | 5.66 Mn | -2.64 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2018 | 95,285.00 |
| Sep 30, 2018 | 227,952.00 |
| Mar 31, 2018 | 10,000.00 |
| Dec 31, 2017 | 90,949.00 |
| Sep 30, 2017 | 5,694.00 |
| Jun 30, 2017 | 175,136.00 |
| Mar 31, 2017 | 209,344.00 |
| Dec 31, 2016 | -45,642.00 |
| Sep 30, 2016 | 1.02 Mn |
| Jun 30, 2016 | 239,815.00 |
| Mar 31, 2016 | 375,405.00 |